ImmuCell Corp. (ICCC)
9.84
-0.06
(-0.61%)
USD |
NASDAQ |
Sep 08, 16:00
9.97
+0.13
(+1.32%)
After-Hours: 20:00
ImmuCell Price to Book Value : 2.848 for Sept. 8, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 2.848 |
| September 04, 2026 | 2.866 |
| September 03, 2026 | 2.895 |
| September 02, 2026 | 2.895 |
| September 01, 2026 | 2.872 |
| August 31, 2026 | 2.834 |
| August 28, 2026 | 2.877 |
| August 27, 2026 | 2.901 |
| August 26, 2026 | 2.901 |
| August 25, 2026 | 2.848 |
| August 24, 2026 | 2.848 |
| August 21, 2026 | 2.912 |
| August 20, 2026 | 2.921 |
| August 19, 2026 | 2.932 |
| August 18, 2026 | 2.825 |
| August 17, 2026 | 2.808 |
| August 14, 2026 | 2.909 |
| August 13, 2026 | 3.155 |
| August 12, 2026 | 3.178 |
| August 11, 2026 | 3.170 |
| August 10, 2026 | 3.176 |
| August 07, 2026 | 3.184 |
| August 06, 2026 | 3.19 |
| August 05, 2026 | 3.112 |
| August 04, 2026 | 3.204 |
| Date | Value |
|---|---|
| August 03, 2026 | 3.196 |
| July 31, 2026 | 3.245 |
| July 30, 2026 | 3.202 |
| July 29, 2026 | 3.187 |
| July 28, 2026 | 3.254 |
| July 27, 2026 | 3.222 |
| July 24, 2026 | 3.193 |
| July 23, 2026 | 3.164 |
| July 22, 2026 | 3.222 |
| July 21, 2026 | 3.241 |
| July 20, 2026 | 3.228 |
| July 17, 2026 | 3.220 |
| July 16, 2026 | 3.222 |
| July 15, 2026 | 3.106 |
| July 14, 2026 | 3.393 |
| July 13, 2026 | 3.207 |
| July 10, 2026 | 3.152 |
| July 09, 2026 | 3.316 |
| July 08, 2026 | 3.077 |
| July 07, 2026 | 2.993 |
| July 06, 2026 | 2.912 |
| July 02, 2026 | 2.979 |
| July 01, 2026 | 3.184 |
| June 30, 2026 | 2.909 |
| June 29, 2026 | 3.077 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.633 |
| Alnylam Pharmaceuticals, Inc. | 25.69 |
| Anika Therapeutics, Inc. | 2.051 |
| Savara, Inc. | 7.907 |
| Vericel Corp. | 5.404 |
Price to Book Value Related Metrics
| PE Ratio | 117.42 |
| PS Ratio | 2.913 |
| Price to Free Cash Flow | 21.20 |
| Price | 9.84 |
| Earnings Yield | 0.85% |
| Market Cap | 89.37M |
| Operating PE Ratio | 47.88 |
| Normalized PE Ratio | 71.36 |